Recruiting

DPA-714 and FDG PET/MRI in Depression

Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between…

ClinicalTrials.gov IDNCT06565936
PhaseNA
Enrollment70
SponsorThe First Affiliated Hospital of Dalian Medical University
Age35 Years
SexALL
I'm interested View official listing

Conditions studied

Depression

About this study

Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. For all groups : * No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination * MMSE≥24 points,MOCA≥26 points * No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks * Patients with diabetes had fasting controlled below 9.0mmol/L before the examination * Volunteer to participate in the study and sign the informed consent 2. For Recurrent depression patients: * Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * Age 35-85 years old, gender is not limited * HAMD≥8 points 3. For first episode depression Patients: * Gender, age and education level were matched with the recurrent depression group * Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) * HAMD≥8 points 4. For controls: * Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital * Gender and education level were consistent with both the recurrent depression group and the first-episode depression group * never used any psychotropic drugs * HAMD\<8 points;HAMA\<7 points Exclusion Criteria(for all groups): * Have a history of organic mental disorders or other mental disorders * A family history of hereditary diseases * Persons with mental retardation or dementia * A history of psychoactive substance abuse * Can not cooperate with/complete the psychological examination scale * Previously found serious physical diseases (heart, brain, liver, lung and kidney) * MRI contraindications, abnormalities found in head CT or MRI * A history of drug or alcohol abuse * Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases * are in the state of pregnancy or breastfeeding

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.